FlowDesk — News

Headlines

Bullish tone

Bearish tone

Symbol-tagged

News sentiment over time

Daily average lexicon sentiment across 198 scored headlines over the last 8 days. For market-wide mood (VIX, breadth, regime), see Markets. For the learned model that predicts forward return from a headline, see Headline Forecast Model.

Yahoo2026-08-30T12:16:57+00:00

Fast Growing ASX Stocks With High Insider Ownership Worth Watching

Rising treasury and sovereign yields driven by persistent inflation concerns are forcing investors to think harder about where future growth might justify the extra risk. This is where fast-growing stocks with high insider ownership become interesting. When management has significant skin in the game, their long-term outlook aligns more closely with yours. This article highlights three stocks from that screener that fit this theme today. The three stocks below are just a small sample of the...

MSB

Yahoo2026-08-29T02:17:11+00:00

PDI Gold Stock Leads These Fast Growing Insider Backed Commodity Picks

Global debt markets are back in focus as the US 10 year yield hovers around the mid 4% range ahead of Jackson Hole. Higher yields can punish weaker balance sheets, yet they often highlight companies that still commit their own capital. This is where fast growing stocks with high insider ownership come in. This article explores three such stocks that align with this theme today. The stocks highlighted below are just a sample, with the full screen surfacing 102 more companies where insiders...

MSB

Yahoo2026-08-27T02:15:11+00:00

Alkane Resources Stock Tops Financially Fit Penny Stocks For Australian Investors

With central banks in several regions still pricing in tighter policy as they watch inflation and growth data, plenty of investors are looking down the market cap spectrum for ideas that do not rely on cheap money to work. That is where the Financially Fit Penny Stocks screener comes in. It filters for lower priced stocks with healthier balance sheets. This article highlights three of the most interesting options from that list. The three stocks below are just a starting sample from this...

MSB

Yahoo2026-08-27T00:24:42+00:00

Why Retail Investors Are Tracking These 3 Founder Led Australian Stocks Today

Energy remains a wild card for inflation, with oil prices and broader energy costs still shaping central bank thinking. When policy can shift quickly, many investors look for something more anchored than quarterly guidance. Founder led companies often fit that bill, with leaders whose own legacies are on the line. This article highlights three founder led stocks from our screener that show how that mindset can matter. The three founder led stocks below are just a starting sample, and the full...

MSB

Yahoo2026-08-26T16:21:58+00:00

3 Australian Growth Stocks With Strong Balance Sheets In A Rate Hike Debate

Central banks are weighing possible further rate hikes to keep inflation in check, which keeps pressure on weaker balance sheets and slower growth stories. Healthy high growth potential stocks can look more attractive in this kind of rate debate, because markets often pay close attention to future earnings strength and financial resilience. This article highlights three stocks from the screener that meet both tests and explains what sets each apart. The three stocks highlighted below are just...

MSB

Yahoo2026-08-27 00:32:00

Mesoblast Reports Substantial Revenue Growth to US$120M

RYONCIL Market Share Expands; Phase 3 Back Pain Trial Completes Treatment Financial Results and Operational Update for Full Year Ended June 30, 2026 NEW YORK, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided financial results and an operational update for the period ended June 30, 2026 (FY2026). Chief Executive of Mesoblast Dr. Silviu Itescu, commented on the result: “We are very p

MESO

Yahoo2026-08-24 11:00:00

Mesoblast Financial Results and Corporate Update Webcast

NEW YORK, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss operational highlights and financial results for the full year ended June 30, 2026. The webcast will begin at 6.30pm EDT, Wednesday, August 26; 8.30am AEST, Thursday, August 27, 2026. It can be accessed via: https://webcast.openbriefing.com/msb-fyr-2026/ The archived webcast will be available on the Investor

MESO

Yahoo2026-08-17 00:35:00

Mesoblast Achieves Major Milestone Completing Patient Treatment in Pivotal Phase 3 Trial for Chronic Low Back Pain

NEW YORK, Aug. 16, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has completed patient treatment in the MSB-DR004 pivotal randomized controlled Phase 3 trial of rexlemestrocel-L for chronic low back pain (CLBP) associated with the inflammatory condition of degenerative disc disease. The major milestone was achieved with 350 patients randomized and treated with either an intra-di

MESO

Diagnostics

sourcesearch:live+archive

count8

archive_hits3

hintWorker/cron → market_news table for the default view; search spans the permanent news_archive plus a live Finnhub top-up